.@BioMoti announces collaboration with global #pharmaceutical company to develop #ovariancancer treatment, BMT101, to clinical phase 2a proof-of-concept and appoints Dr John Beadle as Chairman.
https://t.co/nb8RZhaBqC
Read our new #InspiringWomen Profile of the amazing Professor Joanne Martin- Professor of Pathology at @QMUL and founder of @BioMoti, a company engineering cancer therapeutics to ensure effective treatment with fewer side effects 🔬⬇️👩🔬
https://t.co/H80HZwsPeJ
#WomenInSTEM
Many congratulations to Medi-Immune on the win and thank you to all those who voted for @BioMoti. It was an honour to be shortlisted amongst such great news flow for the sector in 2017! https://t.co/vZbpGUkxi5
ICYMI: Please vote here for us to win: https://t.co/2PGHFmCUx3 @OneNucleus BioNewsRound Award 2017 final. Our story exemplifies resilience as an early stage biotech & our collaborative approach to de-risk our early science to address unmet clinical needs. #Oncojans#ovariancancer
Please vote @BioMoti - shameless plug for our start up, working to bring our ovarian cancer drug delivery system into practice! From microscope observation into potential cancer therapy.... https://t.co/WyuyTQpOgI
@BioMoti, @Pharmidex & @QMUL are proud our @innovateuk#BiomedicalCatalyst funding is a @OneNucleus BioNewsRound Award 2017 finalist. Our story exemplifies resilience & our collaborative approach to de-risk early science. Please vote here for us to win: https://t.co/2PGHFmCUx3